Do you have any advice for pharma companies to ensure they are prepared? “The pharmaceutical industry has primary responsibility for the continuity of supply of medicines and ensuring they are compliant with regulatory requirements. Thus, EMA and EU authorities have been reminding industry of the need to plan and take any necessary regulatory steps to
Director of Academies Nikki Doyle attended the Clinical & Contract Research Association (CCRA) Seminar session on The Landscape for CROs post Brexit. Here she gives her summary of the day: “Having attended a number of forums and talks by various bodies over the past two years where a Brexit update has been merely summarised as
The Clinical Professionals group aim to be aware of the latest industry events and news whilst also aspiring to be at the forefront of the latest analytics and reporting. This enables our consultants to provide a concise and quality service for both clients and candidates, whilst helping the industry to evolve as a whole. Consequently,
In light of the latest Brexit developments, the British Irish Chamber of Commerce released the following press release: Ireland’s largest export market is the UK, with over 16% of all exports going there and approximately 7% of UK exports go to Ireland, making it the UK’s 5th largest export market. The British Irish Chamber of
Clinical Professionals will be attending a vital two-day event hosted by the CCRA on the 29th-30th January at the Royal Society of medicine in London. In an unquestionable time of industrial and economic upheaval across all sectors, the event looks to bring together various key members from Government, the Department of Health, industry regulators and
UK Health secretary Matt Hancock has sought to curb any medicines shortages which could endanger patient health in the event of a ‘no deal’ Brexit from 29 March 2019. Hancock has instructed that the NHS needs to set aside six weeks’ worth of medicines – but according to anti-Brexit campaign group, Best for Britain, this
In a recent statement the MHRA has clarified how the UK’s clinical trials rules will function in partnership with the EU after Britain leaves March next year. “As part of exit negotiations, MHRA is working to ensure that we continue to have the best possible environment in which to support clinical trials,” the agency said.
Lately it has been difficult to not hear, read or see anything Brexit related and it has been clear that it is an event that will undoubtedly alter every industry in the UK, including life sciences. With headlines such as “Sanofi is stockpiling drugs to prepare for a no-deal Brexit” and “EMA cuts back as
Although there have been various warnings about the supply train issues that will happen if a so-called “hard Brexit” occurs, the UK and EU have been unable to refine terms on how drugs will move amongst countries. As a result the NHS is also having to scramble to figure out how to mitigate possible drug
Clinical Professionals will be attending the City & Financial Global’s ‘BREXIT: What does it mean for the Life Sciences’ Summit, which takes place in London on 20th June. The event will examine both short-term and long-term strategies for navigating BREXIT safely and allowing the UK to keep its current status as a leading Life Sciences
